Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins

Journal of Cell Science

Volumn 125, Issue 13, 2012, Pages 3233-3242

  Peng, Lisheng ^a   Berntsson, Ronnie P A ^b   Tepp, William H ^c   Pitkin, Rose M ^a   Johnson, Eric A ^c   Stenmark, Pål ^b   Dong, Min ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Botulinum neurotoxin; Botulinum neurotoxin B; Botulinum toxin; Botulism; Synaptotagmin

Indexed keywords

BOTULINUM NEUROTOXIN D C; BOTULINUM NEUROTOXIN G; BOTULINUM TOXIN; BOTULINUM TOXIN B; BOTULINUM TOXIN C; GANGLIOSIDE; SYNAPTOTAGMIN I; SYNAPTOTAGMIN II; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CHIMPANZEE; HUMAN; IN VIVO STUDY; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; BOTULINUM TOXINS; CELLS, CULTURED; CLOSTRIDIUM BOTULINUM; EXOCYTOSIS; HIPPOCAMPUS; HUMANS; LETHAL DOSE 50; MICE; MOLECULAR SEQUENCE DATA; NEURONS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RATS; RECEPTORS, CELL SURFACE; SYNAPTIC VESICLES; SYNAPTOTAGMIN I; SYNAPTOTAGMIN II;

MUS; PAN; RODENTIA;

EID: 84868382710     PISSN: 00219533     EISSN: 14779137     Source Type: Journal    
DOI: 10.1242/jcs.103564     Document Type: Article

References (54)

1. Arnon, S. S., Schechter, R., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D., Hauer, J., Layton, M. et al. (2001). Botulinum toxin as a biological weapon: medical and public health management. JAMA 285, 1059-1070.
2. Baldwin, M. R. and Barbieri, J. T. (2007). Association of botulinum neurotoxin serotypes a and B with synaptic vesicle protein complexes. Biochemistry 46, 3200-3210.
3. Baldwin, M. R., Tepp, W. H., Przedpelski, A., Pier, C. L., Bradshaw, M., Johnson, E. A. and Barbieri, J. T. (2008). Subunit vaccine against the seven serotypes of botulism. Infect. Immun. 76, 1314-1318.
4. Bennett, M. K., Calakos, N., Kreiner, T. and Scheller, R. H. (1992). Synaptic vesicle membrane proteins interact to form a multimeric complex. J. Cell Biol. 116, 761-775.
5. Benson, M. A., Fu, Z., Kim, J. J. and Baldwin, M. R. (2011). Unique ganglioside recognition strategies for clostridial neurotoxins. J. Biol. Chem. 286, 34015-34022.
6. Boroff, D. A. and Fleck, U. (1966). Statistical analysis of a rapid in vivo method for the titration of the toxin of Clostridium botulinum. J. Bacteriol. 92, 1580-1581.
7. Brin, M. F., Lew, M. F., Adler, C. H., Comella, C. L., Factor, S. A., Jankovic, J., O'Brien, C., Murray, J. J., Wallace, J. D., Willmer-Hulme, A. et al. (1999). Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53, 1431-1438.
8. Chai, Q., Arndt, J. W., Dong, M., Tepp, W. H., Johnson, E. A., Chapman, E. R. and Stevens, R. C. (2006). Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 444, 1096-1100.
9. Craxton, M. (2010). A manual collection of Syt, Esyt, Rph3a, Rph3al, Doc2, and Dblc2 genes from 46 metazoan genomes-an open access resource for neuroscience and evolutionary biology. BMC Genomics 11, 37.
10. Dolly, J. O., Lawrence, G. W., Meng, J., Wang, J. and Ovsepian, S. V. (2009). Neuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeutics. Curr. Opin. Pharmacol. 9, 326-335.
11. Dong, M., Richards, D. A., Goodnough, M. C., Tepp, W. H., Johnson, E. A. and Chapman, E. R. (2003). Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J. Cell Biol. 162, 1293-1303.
12. Dong, M., Yeh, F., Tepp, W. H., Dean, C., Johnson, E. A., Janz, R. and Chapman, E. R. (2006). SV2 is the protein receptor for botulinum neurotoxin A. Science 312, 592-596.
13. Dong, M., Tepp, W. H., Liu, H., Johnson, E. A. and Chapman, E. R. (2007). Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons. J. Cell Biol. 179, 1511-1522.
14. Dong, M., Liu, H., Tepp, W. H., Johnson, E. A., Janz, R. and Chapman, E. R. (2008). Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol. Biol. Cell 19, 5226-5237.
15. Dolly, J. O., Lawrence, G. W., Meng, J., Wang, J. and Ovsepian, S. V. (2009). Neuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeutics. Curr. Opin. Pharmacol. 9, 326-335.
16. Fu, Z., Chen, C., Barbieri, J. T., Kim, J. J. and Baldwin, M. R. (2009). Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. Biochemistry 48, 5631-5641.
17. Hill, K. K., Smith, T. J., Helma, C. H., Ticknor, L. O., Foley, B. T., Svensson, R. T., Brown, J. L., Johnson, E. A., Smith, L. A., Okinaka, R. T. et al. (2007). Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J. Bacteriol. 189, 818-832.
18. Jahn, R. and Scheller, R. H. (2006). SNAREs-engines for membrane fusion. Nat. Rev. Mol. Cell Biol. 7, 631-643.
19. Jin, R., Rummel, A., Binz, T. and Brunger, A. T. (2006). Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 444, 1092-1095.
20. Karalewitz, A. P., Kroken, A. R., Fu, Z., Baldwin, M. R., Kim, J. J. and Barbieri, J. T. (2010). Identification of a unique ganglioside binding loop within botulinum neurotoxins C and D-SA. Biochemistry 49, 8117-8126.
21. Kroken, A. R., Karalewitz, A. P., Fu, Z., Kim, J. J. and Barbieri, J. T. (2011). Novel ganglioside-mediated entry of botulinum neurotoxin serotype D into neurons. J. Biol. Chem. 286, 26828-26837.
22. Lazzell, D. R., Belizaire, R., Thakur, P., Sherry, D. M. and Janz, R. (2004). SV2B regulates synaptotagmin 1 by direct interaction. J. Biol. Chem. 279, 52124-52131.
23. Lindström, M. and Korkeala, H. (2006). Laboratory diagnostics of botulism. Clin. Microbiol. Rev. 19, 298-314.
24. Mahrhold, S., Rummel, A., Bigalke, H., Davletov, B. and Binz, T. (2006). The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. 580, 2011-2014.
25. Montal, M. (2010). Botulinum neurotoxin: a marvel of protein design. Annu. Rev. Biochem. 79, 591-617.
26. Montecucco, C. (1986). How do tetanus and botulinum toxins bind to neuronal membranes? Trends Biochem. Sci. 11, 314-317.
27. Moriishi, K., Koura, M., Abe, N., Fujii, N., Fujinaga, Y., Inoue, K. and Ogumad, K. (1996). Mosaic structures of neurotoxins produced from Clostridium botulinum types C and D organisms. Biochim. Biophys. Acta 1307, 123-126.
28. Muraro, L., Tosatto, S., Motterlini, L., Rossetto, O. and Montecucco, C. (2009). The N-terminal half of the receptor domain of botulinum neurotoxin A binds to microdomains of the plasma membrane. Biochem. Biophys. Res. Commun. 380, 76-80.
29. Nakamura, K., Kohda, T., Umeda, K., Yamamoto, H., Mukamoto, M. and Kozaki, S. (2010). Characterization of the D/C mosaic neurotoxin produced by Clostridium botulinum associated with bovine botulism in Japan. Vet. Microbiol. 140, 147-154.
30. Nishiki, T., Kamata, Y., Nemoto, Y., Omori, A., Ito, T., Takahashi, M. and Kozaki, S. (1994). Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J. Biol. Chem. 269, 10498-10503.
31. Nishiki, T., Tokuyama, Y., Kamata, Y., Nemoto, Y., Yoshida, A., Sato, K., Sekiguchi, M., Takahashi, M. and Kozaki, S. (1996). The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. FEBS Lett. 378, 253-257.
32. Nuemket, N., Tanaka, Y., Tsukamoto, K., Tsuji, T., Nakamura, K., Kozaki, S., Yao, M. and Tanaka, I. (2011). Structural and mutational analyses of the receptor binding domain of botulinum D/C mosaic neurotoxin: insight into the ganglioside binding mechanism. Biochem. Biophys. Res. Commun. 411, 433-439.
33. Pang, Z. P., Melicoff, E., Padgett, D., Liu, Y., Teich, A. F., Dickey, B. F., Lin, W., Adachi, R. and Südhof, T. C. (2006). Synaptotagmin-2 is essential for survival and contributes to Ca2+ triggering of neurotransmitter release in central and neuromus-cular synapses. J. Neurosci. 26, 13493-13504.
34. Pappert, E. J., Germanson, T.; Myobloc/Neurobloc European Cervical Dystonia Study Group (2008). Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial. Mov. Disord. 23, 510-517.
35. Peng, L., Tepp, W. H., Johnson, E. A. and Dong, M. (2011). Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. PLoS Pathog. 7, e1002008.
36. Rummel, A., Mahrhold, S., Bigalke, H. and Binz, T. (2004a). The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol. Microbiol. 51, 631-643.
37. Rummel, A., Karnath, T., Henke, T., Bigalke, H. and Binz, T. (2004b). Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G. J. Biol. Chem. 279, 30865-30870.
38. Rummel, A., Eichner, T., Weil, T., Karnath, T., Gutcaits, A., Mahrhold, S., Sandhoff, K., Proia, R. L., Acharya, K. R., Bigalke, H. et al. (2007). Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc. Natl. Acad. Sci. USA 104, 359-364.
39. Rummel, A., Häfner, K., Mahrhold, S., Darashchonak, N., Holt, M., Jahn, R., Beermann, S., Karnath, T., Bigalke, H. and Binz, T. (2009). Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor. J. Neurochem. 110, 1942-1954.
40. Schiavo, G., Benfenati, F., Poulain, B., Rossetto, O., Polverino de Laureto, P., DasGupta, B. R. and Montecucco, C. (1992). Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359, 832-835.
41. Schiavo, G., Matteoli, M. and Montecucco, C. (2000). Neurotoxins affecting neuroexocytosis. Physiol. Rev. 80, 717-766.
42. Schivell, A. E., Batchelor, R. H. and Bajjalieh, S. M. (1996). Isoform-specific, calcium-regulated interaction of the synaptic vesicle proteins SV2 and synaptotagmin. J. Biol. Chem. 271, 27770-27775.
43. Schmitt, J., Karalewitz, A., Benefield, D. A., Mushrush, D. J., Pruitt, R. N., Spiller, B. W., Barbieri, J. T. and Lacy, D. B. (2010). Structural analysis of botulinum neurotoxin type G receptor binding. Biochemistry 49, 5200-5205.
44. Simpson, L. L. (2004). Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 44, 167-193.
45. Simpson, L. L. and Rapport, M. M. (1971). Ganglioside inactivation of botulinum toxin. J. Neurochem. 18, 1341-1343.
46. Smith, T. J., Lou, J., Geren, I. N., Forsyth, C. M., Tsai, R., Laporte, S. L., Tepp, W. H., Bradshaw, M., Johnson, E. A., Smith, L. A. et al. (2005). Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect. Immun. 73, 5450-5457.
47. Stenmark, P., Dupuy, J., Imamura, A., Kiso, M. and Stevens, R. C. (2008). Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b-insight into the toxin-neuron interaction. PLoS Pathog. 4, e1000129.
48. Stenmark, P., Dong, M., Dupuy, J., Chapman, E. R. and Stevens, R. C. (2010). Crystal structure of the botulinum neurotoxin type G binding domain: insight into cell surface binding. J. Mol. Biol. 397, 1287-1297.
49. Strotmeier, J., Lee, K., Völker, A. K., Mahrhold, S., Zong, Y., Zeiser, J., Zhou, J., Pich, A., Bigalke, H., Binz, T. et al. (2010). Botulinum neurotoxin serotype D attacks neurons via two carbohydrate-binding sites in a ganglioside-dependent manner. Biochem. J. 431, 207-216.
50. Strotmeier, J., Gu, S., Jutzi, S., Mahrhold, S., Zhou, J., Pich, A., Eichner, T., Bigalke, H., Rummel, A., Jin, R. et al. (2011). The biological activity of botulinum neurotoxin type C is dependent upon novel types of ganglioside binding sites. Mol. Microbiol. 81, 143-156.
51. Swaminathan, S. and Eswaramoorthy, S. (2000). Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 7, 693-699.
52. Webb, R. P., Smith, T. J., Wright, P. M., Montgomery, V. A., Meagher, M. M. and Smith, L. A. (2007). Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins. Vaccine 25, 4273-4282.
53. Yao, J., Nowack, A., Kensel-Hammes, P., Gardner, R. G. and Bajjalieh, S. M. (2010). Cotrafficking of SV2 and synaptotagmin at the synapse. J. Neurosci. 30, 5569-5578.
54. Yeh, F. L., Dong, M., Yao, J., Tepp, W. H., Lin, G., Johnson, E. A. and Chapman, E. R. (2010). SV2 mediates entry of tetanus neurotoxin into central neurons. PLoS Pathog. 6, e1001207.